WHO ICTRP trial
Intravenous immunoglobulin rich in neutralising antibodies to SARS-CoV-2…
ACTRN12620001249943 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12620001249943 |
|---|---|
| Public title | Intravenous immunoglobulin rich in neutralising antibodies to SARS-CoV-2 (COVID-19) as a passive immunity modality in healthy individuals: an open-label, active control Phase 1/2 Study |
| Scientific title | Intravenous immunoglobulin rich in neutralising antibodies to SARS-CoV-2 as a passive immunity modality in healthy individuals : an open label, active control Phase 1/2 Study to investigate the safety profile and to characterise the pharmacokinetics of COVID-19 convalescent plasma and hyperimmune… |
| Primary sponsor | Aegros Ltd. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 / Phase 2 |
| Countries | Australia |
| Conditions | COVID-19; COVID-19;Inflammatory and Immune System - Other inflammatory or immune system disorders;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases |
| Interventions | Hyperimmune intravenous immunoglobulin G specific to SARS-CoV-2. Single intravenous infusion of 5% purified IgG formulated to 32mL per vial. Single dose will be 32mL of 5% purified IgG per participant. As there will be only one infusion of… |
| Registration date | Nov 20, 2020 |
| Target size | 30 |
| Secondary IDs | Sponsor ID: AEG-CTP-01 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: